drugset
drugset / Trial / NCT03975010

Buprenorphine Transdermal Patches Pharmacokinetic Study

NCT03975010 ↗

Phase 1 Unknown 45 enrolled Mundipharma (China) Pharmaceutical Co. Ltd
RandomizedParallel-groupOpen-labelBasic science

Summary

This is an open-label, randomised, single-dose, 3 arms study design.

Timeline

Start
2019-05-13
Primary completion
2020-03-31
Completion
2020-03-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 20 mg Other
Subject Buprenorphine Other / unclassified 40 mg Other
Background Naltrexone Small molecule 50 mg Oral

Indications

chronic pain syndrome